This article was originally published in The Gray Sheet
Ongoing internal investigation uncovers improperly recognized revenues in Q4 2003 and Q1 2004 of "less than $75,000 and $125,000, respectively," the gastrointestinal device firm reports. The company cites inappropriate offering of rights for product return and exchange, and a manufacturer rep's improper sales certifications as reasons for the errors. Curon dismissed six sales staffers as a result. In addition to a two-day stock trading hiatus Aug. 17-19 as Nasdaq sought additional information, the investigation will delay filing of the firm's 10-Q second quarter report. Curon also plans an accounting adjustment relating to stock warrants that will cut its Q1 2004 net loss by $450,000-$500,000...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.